Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma

NCT03505944 is registered in ClinicalTrials.gov with Nordic Lymphoma Group as lead sponsor.

NCT NCT03505944
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03505944 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Lead sponsor
Nordic Lymphoma Group
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 1, 2018
Completion date
December 1, 2022
Enrollment
59 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed non hodgkin lymphoma